Drug intelligence / Profile preview

PBGENE-LLY2

Development stage: Unknown
Lead developer: Precision BioSciences
Modality: Gene Therapies

Overview

PBGENE-LLY2 is an investigational gene editing therapy initially developed by Precision BioSciences. It is described in the context of internal Precision BioSciences programs as a liver-directed gene editing candidate, utilizing the ARCUS gene editing platform. The specific genetic targets, mechanism of action, and therapeutic indication for PBGENE-LLY2 have not been publicly disclosed in detail. The program's development status is listed as discontinued, and no active clinical trials or new preclinical data are available as of the latest information[7][11].

Brand names: PBGENE-LLY2PBGENE-LLY-2PBGENE-LLY 2
Other names: PBGENE-LLY2PBGENE-LLY-2PBGENE-LLY 2

Targets

I-CreI site (I-CreI DNA recognition site)

Beyond the preview

Go deeper on PBGENE-LLY2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBGENE-LLY2.

Explore the full profile